Pancreatic Cancer Research Is Moving Forward: Why There Are Reasons for Hope

Pancreatic cancer is one of the most difficult cancers to treat, and the majority of cases are pancreatic ductal adenocarcinoma (PDAC), which is often diagnosed at a late stage. Research initiatives are investigating ways to improve early detection and treatment.

Improving survival rates

Improvements in pancreatic cancer research have been accompanied by improvements in survival rates. Whereas five-year survival rates used to be between 2% and 5%, they are now reported at around 10% to 13%. These are broad population figures, not predictions for an individual. Outcomes can be better when the cancer is fully resectable: some studies report median survival of 54.4 months after resection with FOLFIRINOX compared with 35 months with gemcitabine. Research into neoadjuvant therapy has also shown promising results for the resectability of borderline tumours. Such study results depend on the patients and treatments compared and should not be taken as a guarantee.

Addressing cases that go undetected

One of the biggest issues with pancreatic cancer is that it is often diagnosed at an advanced stage, sometimes after few noticeable symptoms. Research has focused on improved early detection, including imaging and biomarkers that may complement existing diagnostic methods.

Only about 10–15% of patients with pancreatic cancer are diagnosed when the tumour is still restricted to the pancreas and can be completely removed by surgery. Others are diagnosed with locally advanced or metastatic disease. The lack of reliable methods for early detection has prompted considerable research. Studies of people enrolled in high-risk surveillance programmes have documented the potential to detect some cancers at an earlier stage; such programmes are not the same as screening everyone.

Approaches being studied include circulating tumour DNA, tumour-derived signals in body fluids, radiomics and other multi-omics and biomarker methods. These are areas of research, not established population screening tests.

Integrative approaches examine the molecular and cellular make-up of cancer and nearby normal tissue to understand the biological and clinical differences between pancreatic tumours. Cancers that look similar under a microscope can be biologically different.

PDAC can involve changes in genes including KRAS, TP53, CDKN2A and SMAD4. Its molecular heterogeneity matters because it may affect:

• tumour behaviour;
• responses to cancer therapies;
• the development of treatment resistance;
• the potential relevance of different anticancer agents; and
• clinical and research opportunities.

Oncology is moving towards more individualised approaches, and pancreatic cancer research is part of that shift. Chemotherapy remains an important part of care, while trials are investigating neoantigens, cancer vaccines, other immunotherapies and inhibitors of signalling pathways, including for tumours with particular KRAS changes. Many of these strategies remain experimental. The aim is to understand the distinctions between tumours rather than treating every pancreatic tumour as biologically identical.

Pancreatic cancer: why is multi-omics important?

Studying DNA alone may not give a complete picture of a tumour. Multi-omics brings together different kinds of biological information, such as:

• changes in a tumour's DNA;
• which genes are expressed;
• mechanisms that affect gene expression;
• differences among the cells within a tumour;
• proteins and other molecules produced by a tumour; and
• genetic material released by a tumour.

Integrating these layers may produce a more detailed molecular profile and support research into potential treatment strategies. This is also a focus of the DTwin and OmixMe research analyses, studying tumours across several biological dimensions to better understand the disease. Additional information is available upon request at contact@omixme.com.

This article is for informational and educational purposes only. It is not medical advice and does not replace consultation with a qualified clinician. Diagnosis and treatment decisions belong with the treating medical team.